Meeting
2013 ASCO Annual Meeting
Next-generation sequencing to find predictors for chemotherapy response in triple-negative breast cancer (TNBC).
Authors
Esther H. Lips
Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, Netherlands
Esther H. Lips , Magali Michaut , Lennart Mulder , Nicolle Besselink , Marlous L. Hoogstraat , Marco J. Koudijs , Emile E. Voest , Rene Bernards , Jelle Wesseling , Lodewyk F. A. Wessels , Sjoerd Rodenhuis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1010)
DOI
10.1200/jco.2013.31.15_suppl.1010
Abstract #
1010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Transcriptomic and protein expression analysis of helicase antigen (HAGE) in triple negative breast cancer (TNBC) as a novel prognostic and predictive biomarker.
First Author: Tarek M. A. Abdel-Fatah
Poster
2014 ASCO Annual Meeting
The role of CHFR as a predictive marker of response to taxane-based preoperative chemotherapy in triple-negative breast cancer.
First Author: Elisavet Paplomata
Poster
2011 ASCO Annual Meeting
Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial.
First Author: K. Shen
Poster
2011 ASCO Annual Meeting
Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).
First Author: A. M. Gonzalez-Angulo